The development of pharmacological approaches for female sexual dysfunction (FSD) and particularly female sexual arousal disorder (FSAD) has been facilitated by the recent advancement in de®nitions and classi®cations of FSD and by the development of validated instruments to measure outcomes including the Female Sexual Function Index (FSFI). This state-of-the-art review will examine the current available data on the utilization of vasoactive drug therapy for female arousal disorder.
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In contrast to the Masters and Johnson linear model of the female sexual response cycle (desire leading to arousal leading to orgasm), Besson has recently proposed that perhaps, unlike the male, the female sexual response cycle may be more`circular'. She has proposed that a more realistic model, particularly in longer-term relationships, is one where most women are neutral in desire but make a deliberate choice to experience stimulation, mainly for the`spin-offs' including emotional closeness, bonding, commitment, love, affection, acceptance, toleration and closeness. In such a model, this receptivity facilitates arousal, which then increases desire. This alternative model was proposed to improve the behavioural, psychological and pharmacological treatment of female sexual dysfunction.
Female sexual arousal disorder is de®ned as the persistent or recurrent inability to attain andaor maintain suf®cient sexual excitement, causing personal distress which may be expressed as a lack of subjective excitement, or genital (lubricationa swelling) or other somatic responses (International Consensus Conference on Female Sexual Dysfunction, 1999). Sexual arousal dysfunction was, until recently, an infrequently diagnosed female sexual dysfunction. However, in light of the new model proposed by Besson that underscores the importance of arousal, particularly its subjective component, it may be in fact a more common disorder than previously appreciated.
Currently there are a plethora of clinical trials underway evaluating the ef®cacy and safety of a number of oral vasoactive drugs in the treatment of female sexual arousal disorder including Sidlena®l and other PDE5 inhibitors. Apomorphine SL and the combination of L-Arginine and Yohimbine. Most of these studies are at a phase 2 level. A great deal of anecdotal reports as well as poorly designed studies (lacking placebo control, randomization or blinding) employing non-validated instruments have predominated the reports of ef®cacy of Sildenadil in FSAD to date. However, Besson and associates recently presented the ®rst large-scale double blind, placebo controlled randomized clinical trial of Sildena®l in FSAD. 583 women with FSAD as the primary presenting symptom (28%), orgasmic disorder (17%) or dyspareunia (9%) were randomized to treatment. the doses examined in this¯exible dose study included 10, 25 and 50 mg taken on a prn basis over a 12-week study interval. Ef®cacy was measured by a sexual function questionnaire, the Lifestyle Satisfaction Checklist and an event log of sexual activity. The results demonstrated no difference in response between the active drug dosages and placebo. The adverse events included, as expected, headaches,¯ushing, rhinitis, nausea, altered vision and dyspepsia. These were generally mild to moderate in severity. One patient experienced a serious treatment-related adverse event, menorrhagia. Despite the results of this large phase 2 Sildena®l study, there is still promise that vasoactive drugs may ultimately play a role in the management of FSAD but perhaps only in carefully selected patients or in speci®c subpopulations such as the post-hysterectomy BSO patient with FSAD despite adequate hormonal (E and T) replacement therapy or in the patient with SSRI-induced FSAD.
